EMROSI Drug Patent Profile
Which patents cover Emrosi, and what generic alternatives are available?
Emrosi is a drug marketed by Journey and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in EMROSI is minocycline hydrochloride. Twenty-three suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emrosi
A generic version of EMROSI was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EMROSI?
- What are the global sales for EMROSI?
- What is Average Wholesale Price for EMROSI?
Summary for EMROSI
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EMROSI |
Paragraph IV (Patent) Challenges for EMROSI
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EMROSI | Extended-release Capsules | minocycline hydrochloride | 40 mg | 219015 | 1 | 2025-12-16 |
US Patents and Regulatory Information for EMROSI
EMROSI is protected by four US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | EMROSI | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 219015-001 | Nov 1, 2024 | RX | Yes | Yes | 11,364,212 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Journey | EMROSI | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 219015-001 | Nov 1, 2024 | RX | Yes | Yes | 12,594,252 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Journey | EMROSI | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 219015-001 | Nov 1, 2024 | RX | Yes | Yes | 11,191,740 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Journey | EMROSI | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 219015-001 | Nov 1, 2024 | RX | Yes | Yes | 10,905,664 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Journey | EMROSI | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 219015-001 | Nov 1, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EMROSI
See the table below for patents covering EMROSI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2019205134 | Minocycline for treating inflammatory skin conditions | ⤷ Start Trial |
| Australia | 2025200826 | Minocycline for treating inflammatory skin conditions | ⤷ Start Trial |
| Brazil | 112020013789 | métodos para o tratamento de afecções cutâneas inflamatórias | ⤷ Start Trial |
| Canada | 3087838 | MINOCYCLINE POUR LE TRAITEMENT D'AFFECTIONS INFLAMMATOIRES DE LA PEAU (MINOCYCLINE FOR TREATING INFLAMMATORY SKIN CONDITIONS) | ⤷ Start Trial |
| China | 111818927 | 用于治疗炎性皮肤疾病的米诺环素 (Minocycline for treating inflammatory skin conditions) | ⤷ Start Trial |
| Eurasian Patent Organization | 202091653 | МИНОЦИКЛИН ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ КОЖИ | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch